查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2133631

ADHD數位療法市場預測至2034年—按產品類型、年齡層、交付平台、經營模式、應用、最終用戶和地區分類的全球分析

Digital Therapeutics for ADHD Market Forecasts to 2034 - Global Analysis By Product Type, Age Group, Delivery Platform, Business Model, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球 ADHD 數位療法市場規模將達到 15 億美元，並在預測期內以 20.7% 的複合年成長率成長，到 2034 年將達到 68 億美元。

針對注意力不足過動症 (ADHD) 的數位療法是基於循證醫學的軟體應用程式，可透過智慧型手機、平板電腦、個人電腦和穿戴式裝置使用。這些應用程式以遊戲化、互動式的形式，透過認知訓練、行為療法、神經回饋和注意力調節練習等機制，為 ADHD 患者提供治療性介入。這些數位介入措施，部分需要處方箋，部分則無需處方，旨在透過反覆參與經科學檢驗的治療方案，改善患者的注意力、衝動控制、執行功能和行為自控能力。它們可以與藥物聯合使用，也可以作為尋求非藥物治療 ADHD 患者的獨立治療選擇。

ADHD藥物取得障礙

傳統過動症藥物取得的障礙，例如興奮劑供不應求、處方監管限制、對副作用的擔憂以及患者對非藥物療法的偏好，正推動著人們對數位療法作為注意力不足過動症（ADHD）可行替代或輔助治療方案的顯著需求。兒童、青少年和成人ADHD診斷率的不斷上升，造成了巨大的治療需求，而傳統的藥品供應鏈無法完全滿足這些需求。同時，患者對興奮劑副作用的擔憂也促使他們更加關注FDA已通過核准的數位治療方案。隨著醫療專業人員日益認可數位療法作為實證干預措施，其處方和推薦趨勢也不斷擴大。

保險報銷範圍的限制

有限的保險覆蓋範圍和保險公司對過動症數位藥物的低接受度是限制市場發展的因素。許多健康保險計劃和政府醫療保健項目缺乏處方箋類數位藥物的既定政策，導致患者自付費用較高，限制了藥物獲取，阻礙了市場擴張。保險核准流程需要大量的臨床證據和成本效益數據，而數位藥物公司必須透過成本高昂的臨床試驗來獲得這些數據。同時，由於缺乏成熟的保險保障途徑，醫療服務提供者在開立處方時也較為謹慎。美國分散的工資發放制度以及國際上多樣化的報銷體系，都使數位藥物公司進入市場變得更加複雜。

與兒童心理健康服務機構合作

與兒童心理健康服務的整合為過動症數位療法帶來了巨大的市場機會。目前，兒童過動症治療的現有需求已為數位療法的推廣提供了途徑，包括兒童醫院、行為健康中心、學校衛生服務機構以及兒童精神科醫生網路。在臨床環境中部署的數位療法能夠確保患者在兩次就診之間持續接受治療，同時提供客觀的療效數據，用於監測和調整治療方案。隨著對兒童心理健康基礎設施（例如校內心理健康服務和遠端醫療平台）的投資日益重要，過動症數位療法的市場准入機會也不斷擴大。

與健康應用程式的競爭

來自免費或低價健康應用程式的競爭仍然構成持續的市場威脅，這些應用程式提供注意力訓練和認知練習，但缺乏臨床證據支持。這是因為消費者往往無法區分經過臨床檢驗、僅憑處方箋才能購買的數位療法和缺乏針對多動症特定療效科學依據的普通健康應用程式。應用程式商店中大量湧現的注意力增強應用程式令消費者感到困惑，並對循證數位療法造成了價格壓力。同時，醫療保健專業人員對健康應用程式和受監管的數位療法之間的產品差異缺乏了解，限制了處方箋的使用。此外，不同司法管轄區對健康應用程式中未經證實的臨床療效聲明的監管強度也不一致。

新型冠狀病毒（COVID-19）的影響：

新冠疫情顯著加速了注意力不足過動症（ADHD）數位療法市場的發展，這得益於遠距遠端醫療服務的廣泛應用、遠距監測能力的提升，以及在疫情導致的醫療服務受限情況下，人們普遍認知到數位干預是必要的醫療保健工具。疫情期間，遠距辦公、線上學習以及疫情相關的壓力加劇了各年齡層的注意力缺陷和執行功能障礙，從而增加了對ADHD診斷和治療的需求。疫情後的結構性影響包括：數位療法永久融入醫療保健體系、保險覆蓋範圍擴大，以及將數位心理健康工具整合到標準的ADHD治療方案中。

在預測期內，處方箋數位療法領域預計將佔據最大的市場佔有率。

預計在預測期內，處方箋數位療法領域將佔據最大的市場佔有率。這是因為FDA批准處方箋藥數位療法用於治療ADHD，增強了臨床醫生、醫療服務提供者和患者的信心，使他們更加信任那些經過驗證的、安全有效的受監管數位干預措施。處方箋數位療法受益於醫生已建立的處方模式，這些模式將數位介入措施整合到傳統的ADHD治療方案中。與未經監管的健康應用程式相比，FDA已通過核准的治療產品更有可能獲得保險報銷。處方箋要求為臨床監督和患者參與建立了途徑，從而最佳化治療效果並促進市場成長。

預計在預測期內，基於行動應用程式的治療領域將呈現最高的複合年成長率。

在預測期內，行動應用治療領域預計將呈現最高的成長率，這主要得益於智慧型手機的廣泛普及以及行動治療性介入在支持日常生活中過動症管理方面的諸多優勢，例如便捷性、易用性和更高的患者參與度。行動應用治療透過推播通知、進展追蹤和遊戲化介面，能夠實現持續的患者參與，從而提高患者對治療的依從性，優於診所和基於網路的替代方案。行動應用透過應用程式商店和數位處方系統進行擴充性，這不僅能夠快速拓展市場，還能降低每位患者的額外成本。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。這主要歸功於北美地區最高的注意力不足過動症（ADHD）診斷率、美國食品藥物管理局（FDA）已建立的處方數位療法法規結構、有利於數位健康干預措施的報銷環境，以及包括Akili公司和Pear Therapeutics公司在內的眾多數位療法公司在該地區的集中。美國正透過積極在臨床實踐中採用數位療法、醫療保健行業的創新文化以及風險投資和大型醫療保健公司對數位心理健康解決方案的大量投資，推動著創業投資需求的成長。隨著聯邦政府將數位療法認定為符合保險報銷條件的醫療干預措施，市場准入正在不斷擴大。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於人們對多動症診斷的認知度不斷提高、亞洲社會對心理健康的接受度增強、醫療保健支出不斷成長，以及中國、日本、韓國和澳大利亞等國數位醫療基礎設施的不斷完善。中國對數位醫療政策的重視以及對兒童心理健康需求的日益關注，促使各機構對多動症數位藥物的興趣日益濃厚；同時，遠端醫療的普及也改善了即使在服務不足地區也能獲得專業多動症診斷和治療的機會。針對不同文化背景開發的數位藥物和本地語言應用程式正在推動市場滲透。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球過動症數位療法市場：依產品類型分類

  • 僅限處方箋的數位藥物
  • 無需處方箋即可購買的數位藥物
  • 以軟體為基礎的治療方案
  • 利用電子遊戲進行治療的方法
  • 基於行動應用程式的治療
  • 網路為基礎的治療平台

第6章：全球過動症數位療法市場：依年齡層別分類

  • 孩子們
  • 青春期
  • 成人
  • 老年人

第7章：全球過動症數位療法市場：按分銷平台分類

  • 智慧型手機
  • 藥片
  • 個人電腦
  • 穿戴式裝置
  • 網路為基礎的平台

第8章：全球過動症數位療法市場：以經營模式

  • 基於訂閱
  • 大量購買
  • 保險報銷類型
  • 雇主主導
  • 由醫療保健提供者主導

第9章：全球過動症數位療法市場：按應用領域分類

  • 注意力訓練
  • 脈衝控制
  • 認知功能改善
  • 行為管理
  • 藥物依從性支持
  • 遠端患者監護
  • 其他用途

第10章：全球過動症數位療法市場：以最終用戶分類

  • 醫院和診所
  • 行為醫學中心
  • 學術和研究機構
  • 居家照護環境
  • 個人用戶
  • 其他最終用戶

第11章：全球過動症數位療法市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Akili, Inc.
  • Pear Therapeutics, Inc.
  • Big Health, Inc.
  • Limbix Health, Inc.
  • EndeavorRx
  • Monument Therapeutics
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Medtronic plc
  • Omada Health, Inc.
  • DarioHealth Corp.
  • Click Therapeutics, Inc.
  • Woebot Health
  • Headspace Health
  • Better Therapeutics, Inc.
  • X2AI, Inc.
  • Cognoa, Inc.
Product Code: SMRC39558

According to Stratistics MRC, the Global Digital Therapeutics for ADHD Market is accounted for $1.5 billion in 2026 and is expected to reach $6.8 billion by 2034 growing at a CAGR of 20.7% during the forecast period. Digital therapeutics for ADHD are evidence-based software applications delivered via smartphones, tablets, personal computers, and wearable devices that provide therapeutic interventions for attention deficit hyperactivity disorder through mechanisms including cognitive training, behavioral therapy, neurofeedback, and attention regulation exercises delivered in gamified and interactive formats. These prescription and non-prescription digital interventions are designed to improve attention capacity, impulse control, executive function, and behavioral self-regulation through repeated engagement with scientifically validated therapeutic protocols, often prescribed in conjunction with pharmacotherapy or as standalone treatment alternatives for patients seeking non-pharmacological ADHD management options.

Market Dynamics:

Driver:

ADHD Medication Access Barriers

Access barriers to traditional ADHD medications, including stimulant shortages, prescription regulatory restrictions, side effect concerns, and patient preference for non-pharmacological treatment options, are driving significant demand for digital therapeutics as viable alternative or complementary treatment approaches for attention deficit hyperactivity disorder. The increasing diagnosis rates of ADHD across pediatric, adolescent, and adult populations have created substantial treatment demand that conventional medication supply chains cannot fully satisfy, while patient concerns regarding stimulant side effects have motivated interest in FDA-cleared digital treatment options. Healthcare provider recognition of digital therapeutics as evidence-based interventions is expanding prescription and recommendation patterns.

Restraint:

Reimbursement Coverage Limitations

Limited reimbursement coverage and payer acceptance of digital therapeutics for ADHD represent significant market restraints, as many health insurance plans and government healthcare programs have not established adequate coverage policies for prescription digital therapeutics, creating out-of-pocket cost barriers that restrict patient access and limit market expansion. Reimbursement approval processes require extensive clinical evidence and cost-effectiveness data that digital therapeutic companies must generate through expensive clinical trials, while healthcare provider prescribing patterns remain cautious without established reimbursement pathways. The fragmented US payer landscape and diverse international reimbursement systems create market access complexity for digital therapeutic companies.

Opportunity:

Pediatric Mental Health Integration

Integration with pediatric mental health services presents a significant market opportunity for ADHD digital therapeutics, as the established demand for pediatric ADHD treatment creates ready adoption pathways through children's hospitals, behavioral health centers, school-based health services, and pediatric mental health specialist networks. Digital therapeutics deployed in clinical settings enable continuous therapeutic engagement between clinical appointments while providing objective performance data for treatment monitoring and adjustment. The growing emphasis on pediatric mental health infrastructure investment, including school-based mental health services and telehealth platforms, is expanding market access points for ADHD digital therapeutic products.

Threat:

Competition from Wellness Apps

Competition from free or low-cost wellness applications offering attention training and cognitive exercises without clinical evidence requirements constitutes a persistent market threat, as consumers often cannot distinguish between clinically validated prescription digital therapeutics and general wellness apps that lack scientific substantiation for ADHD-specific therapeutic claims. The proliferation of attention-focused applications in app stores creates consumer confusion and price pressure on evidence-based digital therapeutics, while limited healthcare provider awareness of product differentiation between wellness apps and regulated digital therapeutics restricts prescription adoption. Regulatory enforcement against unsubstantiated clinical claims in wellness apps remains inconsistent across jurisdictions.

Covid-19 Impact:

COVID-19 significantly accelerated the digital therapeutics for ADHD market through widespread adoption of telehealth services, increased remote monitoring capabilities, and expanded recognition of digital interventions as essential healthcare tools during pandemic-related healthcare access restrictions. The pandemic increased ADHD diagnosis and treatment demand as remote work, online schooling, and pandemic-related stress exacerbated attention and executive function challenges across populations. Post-pandemic structural impacts include permanent acceptance of digital therapeutics in healthcare delivery, expanded insurance coverage recognition, and integration of digital mental health tools into mainstream ADHD treatment protocols.

The prescription digital therapeutics segment is expected to be the largest during the forecast period

The prescription digital therapeutics segment is expected to account for the largest market share during the forecast period, due to the FDA clearance of prescription digital therapeutics for ADHD treatment generating clinical credibility, healthcare provider confidence, and patient trust in regulated digital interventions with demonstrated safety and efficacy evidence. Prescription digital therapeutics benefit from established physician prescribing patterns that integrate digital interventions with conventional ADHD treatment protocols, while reimbursement coverage is more likely for FDA-cleared therapeutic products compared to unregulated wellness applications. The prescription requirement creates clinical oversight and patient engagement pathways that optimize treatment outcomes and support market growth.

The mobile application-based therapeutics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the mobile application-based therapeutics segment is predicted to witness the highest growth rate, driven by the ubiquitous availability of smartphones and the convenience, accessibility, and engagement advantages of mobile-delivered therapeutic interventions that support daily ADHD management in real-world contexts. Mobile application therapeutics enable continuous patient engagement through push notifications, progress tracking, and gamified interfaces that increase treatment adherence compared to clinic-based or web-based alternatives. The scalability of mobile application distribution through app stores and digital prescription systems enables rapid market expansion and reduced incremental costs per patient.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the highest diagnosed ADHD prevalence rates, established regulatory framework for prescription digital therapeutics through the FDA, favorable reimbursement environment for digital health interventions, and concentration of digital therapeutic companies including Akili, Inc. and Pear Therapeutics, Inc. The United States leads regional demand through strong clinical adoption of digital therapeutics, healthcare innovation culture, and substantial investment in digital mental health solutions from venture capital and established healthcare companies. Federal recognition of digital therapeutics as reimbursable health interventions is expanding market access.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to increasing ADHD diagnosis awareness, growing mental health acceptance across Asian societies, rising healthcare spending, and expanding digital health infrastructure in China, Japan, South Korea, and Australia. China's digital health policy emphasis and growing recognition of pediatric mental health needs are driving institutional interest in ADHD digital therapeutics, while telemedicine expansion increases access to specialized ADHD diagnosis and treatment in underserved regions. Regional development of culturally adapted digital therapeutics and local language applications is supporting market penetration.

Key players in the market

Some of the key players in Digital Therapeutics for ADHD Market include Akili, Inc., Pear Therapeutics, Inc., Big Health, Inc., Limbix Health, Inc., EndeavorRx, Monument Therapeutics, Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Medtronic plc, Omada Health, Inc., DarioHealth Corp., Click Therapeutics, Inc., Woebot Health, Headspace Health, Better Therapeutics, Inc., X2AI, Inc., and Cognoa, Inc.

Key Developments:

In August 2026, Akili, Inc. received expanded FDA clearance for its pediatric ADHD digital therapeutic, enabling broader clinical adoption and improving access to digital treatment options for children with ADHD.

In July 2026, Pear Therapeutics, Inc. announced positive clinical trial results for its adult ADHD digital therapeutic, demonstrating significant symptom improvement and strengthening evidence supporting digital interventions for adult ADHD management.

In June 2026, Click Therapeutics, Inc. launched a new mobile-based ADHD therapeutic targeting executive function deficits with gamified cognitive training modules, supporting personalized treatment and improving engagement among patients.

Product Types Covered:

  • Prescription Digital Therapeutics
  • Non-Prescription Digital Therapeutics
  • Software-Based Therapeutic Programs
  • Video Game-Based Therapeutics
  • Mobile Application-Based Therapeutics
  • Web-Based Therapeutic Platforms

Age Groups Covered:

  • Children
  • Adolescents
  • Adults
  • Older Adults

Delivery Platforms Covered:

  • Smartphones
  • Tablets
  • Personal Computers
  • Wearable Devices
  • Web-Based Platforms

Business Models Covered:

  • Subscription-Based
  • One-Time Purchase
  • Reimbursement-Based
  • Employer-Sponsored
  • Healthcare Provider-Sponsored

Applications Covered:

  • Attention Training
  • Impulse Control
  • Cognitive Function Improvement
  • Behavioral Management
  • Medication Adherence Support
  • Remote Patient Monitoring
  • Other Applications

End Users Covered:

  • Hospitals and Clinics
  • Behavioral Health Centers
  • Academic and Research Institutions
  • Homecare Settings
  • Individual Users
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Digital Therapeutics for ADHD Market, By Product Type

  • 5.1 Prescription Digital Therapeutics
  • 5.2 Non-Prescription Digital Therapeutics
  • 5.3 Software-Based Therapeutic Programs
  • 5.4 Video Game-Based Therapeutics
  • 5.5 Mobile Application-Based Therapeutics
  • 5.6 Web-Based Therapeutic Platforms

6 Global Digital Therapeutics for ADHD Market, By Age Group

  • 6.1 Children
  • 6.2 Adolescents
  • 6.3 Adults
  • 6.4 Older Adults

7 Global Digital Therapeutics for ADHD Market, By Delivery Platform

  • 7.1 Smartphones
  • 7.2 Tablets
  • 7.3 Personal Computers
  • 7.4 Wearable Devices
  • 7.5 Web-Based Platforms

8 Global Digital Therapeutics for ADHD Market, By Business Model

  • 8.1 Subscription-Based
  • 8.2 One-Time Purchase
  • 8.3 Reimbursement-Based
  • 8.4 Employer-Sponsored
  • 8.5 Healthcare Provider-Sponsored

9 Global Digital Therapeutics for ADHD Market, By Application

  • 9.1 Attention Training
  • 9.2 Impulse Control
  • 9.3 Cognitive Function Improvement
  • 9.4 Behavioral Management
  • 9.5 Medication Adherence Support
  • 9.6 Remote Patient Monitoring
  • 9.7 Other Applications

10 Global Digital Therapeutics for ADHD Market, By End User

  • 10.1 Hospitals and Clinics
  • 10.2 Behavioral Health Centers
  • 10.3 Academic and Research Institutions
  • 10.4 Homecare Settings
  • 10.5 Individual Users
  • 10.6 Other End Users

11 Global Digital Therapeutics for ADHD Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Akili, Inc.
  • 14.2 Pear Therapeutics, Inc.
  • 14.3 Big Health, Inc.
  • 14.4 Limbix Health, Inc.
  • 14.5 EndeavorRx
  • 14.6 Monument Therapeutics
  • 14.7 Otsuka Pharmaceutical Co., Ltd.
  • 14.8 Takeda Pharmaceutical Company Limited
  • 14.9 Medtronic plc
  • 14.10 Omada Health, Inc.
  • 14.11 DarioHealth Corp.
  • 14.12 Click Therapeutics, Inc.
  • 14.13 Woebot Health
  • 14.14 Headspace Health
  • 14.15 Better Therapeutics, Inc.
  • 14.16 X2AI, Inc.
  • 14.17 Cognoa, Inc.

List of Tables

  • Table 1 Global Digital Therapeutics for ADHD Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Digital Therapeutics for ADHD Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Digital Therapeutics for ADHD Market Outlook, By Prescription Digital Therapeutics (2023-2034) ($MN)
  • Table 4 Global Digital Therapeutics for ADHD Market Outlook, By Non-Prescription Digital Therapeutics (2023-2034) ($MN)
  • Table 5 Global Digital Therapeutics for ADHD Market Outlook, By Software-Based Therapeutic Programs (2023-2034) ($MN)
  • Table 6 Global Digital Therapeutics for ADHD Market Outlook, By Video Game-Based Therapeutics (2023-2034) ($MN)
  • Table 7 Global Digital Therapeutics for ADHD Market Outlook, By Mobile Application-Based Therapeutics (2023-2034) ($MN)
  • Table 8 Global Digital Therapeutics for ADHD Market Outlook, By Web-Based Therapeutic Platforms (2023-2034) ($MN)
  • Table 9 Global Digital Therapeutics for ADHD Market Outlook, By Age Group (2023-2034) ($MN)
  • Table 10 Global Digital Therapeutics for ADHD Market Outlook, By Children (2023-2034) ($MN)
  • Table 11 Global Digital Therapeutics for ADHD Market Outlook, By Adolescents (2023-2034) ($MN)
  • Table 12 Global Digital Therapeutics for ADHD Market Outlook, By Adults (2023-2034) ($MN)
  • Table 13 Global Digital Therapeutics for ADHD Market Outlook, By Older Adults (2023-2034) ($MN)
  • Table 14 Global Digital Therapeutics for ADHD Market Outlook, By Delivery Platform (2023-2034) ($MN)
  • Table 15 Global Digital Therapeutics for ADHD Market Outlook, By Smartphones (2023-2034) ($MN)
  • Table 16 Global Digital Therapeutics for ADHD Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 17 Global Digital Therapeutics for ADHD Market Outlook, By Personal Computers (2023-2034) ($MN)
  • Table 18 Global Digital Therapeutics for ADHD Market Outlook, By Wearable Devices (2023-2034) ($MN)
  • Table 19 Global Digital Therapeutics for ADHD Market Outlook, By Web-Based Platforms (2023-2034) ($MN)
  • Table 20 Global Digital Therapeutics for ADHD Market Outlook, By Business Model (2023-2034) ($MN)
  • Table 21 Global Digital Therapeutics for ADHD Market Outlook, By Subscription-Based (2023-2034) ($MN)
  • Table 22 Global Digital Therapeutics for ADHD Market Outlook, By One-Time Purchase (2023-2034) ($MN)
  • Table 23 Global Digital Therapeutics for ADHD Market Outlook, By Reimbursement-Based (2023-2034) ($MN)
  • Table 24 Global Digital Therapeutics for ADHD Market Outlook, By Employer-Sponsored (2023-2034) ($MN)
  • Table 25 Global Digital Therapeutics for ADHD Market Outlook, By Healthcare Provider-Sponsored (2023-2034) ($MN)
  • Table 26 Global Digital Therapeutics for ADHD Market Outlook, By Application (2023-2034) ($MN)
  • Table 27 Global Digital Therapeutics for ADHD Market Outlook, By Attention Training (2023-2034) ($MN)
  • Table 28 Global Digital Therapeutics for ADHD Market Outlook, By Impulse Control (2023-2034) ($MN)
  • Table 29 Global Digital Therapeutics for ADHD Market Outlook, By Cognitive Function Improvement (2023-2034) ($MN)
  • Table 30 Global Digital Therapeutics for ADHD Market Outlook, By Behavioral Management (2023-2034) ($MN)
  • Table 31 Global Digital Therapeutics for ADHD Market Outlook, By Medication Adherence Support (2023-2034) ($MN)
  • Table 32 Global Digital Therapeutics for ADHD Market Outlook, By Remote Patient Monitoring (2023-2034) ($MN)
  • Table 33 Global Digital Therapeutics for ADHD Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 34 Global Digital Therapeutics for ADHD Market Outlook, By End User (2023-2034) ($MN)
  • Table 35 Global Digital Therapeutics for ADHD Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 36 Global Digital Therapeutics for ADHD Market Outlook, By Behavioral Health Centers (2023-2034) ($MN)
  • Table 37 Global Digital Therapeutics for ADHD Market Outlook, By Academic and Research Institutions (2023-2034) ($MN)
  • Table 38 Global Digital Therapeutics for ADHD Market Outlook, By Homecare Settings (2023-2034) ($MN)
  • Table 39 Global Digital Therapeutics for ADHD Market Outlook, By Individual Users (2023-2034) ($MN)
  • Table 40 Global Digital Therapeutics for ADHD Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.